Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,604 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial).
Sato Y, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Ando M, Tsuda K, Iwata O, Muramatsu Y, Kidokoro H, Hirakawa A, Hayakawa M; SHEILD team. Sato Y, et al. Among authors: shimizu s. Stem Cells Transl Med. 2024 Oct 14:szae071. doi: 10.1093/stcltm/szae071. Online ahead of print. Stem Cells Transl Med. 2024. PMID: 39401019 Free article.
Safety and tolerability of a multilineage-differentiating stress-enduring cell-based product in neonatal hypoxic-ischaemic encephalopathy with therapeutic hypothermia (SHIELD trial): a clinical trial protocol open-label, non-randomised, dose-escalation trial.
Matsuyama N, Shimizu S, Ueda K, Suzuki T, Suzuki S, Miura R, Katayama A, Ando M, Mizuno M, Hirakawa A, Hayakawa M, Sato Y. Matsuyama N, et al. Among authors: shimizu s. BMJ Open. 2022 Apr 26;12(4):e057073. doi: 10.1136/bmjopen-2021-057073. BMJ Open. 2022. PMID: 35473726 Free PMC article. Clinical Trial.
A Novel Treatment with Stem Cells from Human Exfoliated Deciduous Teeth for Hypoxic-Ischemic Encephalopathy in Neonatal Rats.
Kitase Y, Sato Y, Ueda K, Suzuki T, Mikrogeorgiou A, Sugiyama Y, Matsubara K, Tsukagoshi Okabe Y, Shimizu S, Hirata H, Yukawa H, Baba Y, Tsuji M, Takahashi Y, Yamamoto A, Hayakawa M. Kitase Y, et al. Among authors: shimizu s. Stem Cells Dev. 2020 Jan 15;29(2):63-74. doi: 10.1089/scd.2019.0221. Stem Cells Dev. 2020. PMID: 31801412
Systemic administration of clinical-grade multilineage-differentiating stress-enduring cells ameliorates hypoxic-ischemic brain injury in neonatal rats.
Ueda K, Sato Y, Shimizu S, Suzuki T, Onoda A, Miura R, Go S, Mimatsu H, Kitase Y, Yamashita Y, Irie K, Tsuji M, Mishima K, Mizuno M, Takahashi Y, Dezawa M, Hayakawa M. Ueda K, et al. Among authors: shimizu s. Sci Rep. 2023 Sep 11;13(1):14958. doi: 10.1038/s41598-023-41026-3. Sci Rep. 2023. PMID: 37696826 Free PMC article.
Intravenously delivered multilineage-differentiating stress enduring cells dampen excessive glutamate metabolism and microglial activation in experimental perinatal hypoxic ischemic encephalopathy.
Suzuki T, Sato Y, Kushida Y, Tsuji M, Wakao S, Ueda K, Imai K, Iitani Y, Shimizu S, Hida H, Temma T, Saito S, Iida H, Mizuno M, Takahashi Y, Dezawa M, Borlongan CV, Hayakawa M. Suzuki T, et al. Among authors: shimizu s. J Cereb Blood Flow Metab. 2021 Jul;41(7):1707-1720. doi: 10.1177/0271678X20972656. Epub 2020 Nov 22. J Cereb Blood Flow Metab. 2021. PMID: 33222596 Free PMC article.
Mexiletine in spinal and bulbar muscular atrophy: a randomized controlled trial.
Yamada S, Hashizume A, Hijikata Y, Inagaki T, Ito D, Kishimoto Y, Kinoshita F, Hirakawa A, Shimizu S, Nakamura T, Katsuno M. Yamada S, et al. Among authors: shimizu s. Ann Clin Transl Neurol. 2022 Nov;9(11):1702-1714. doi: 10.1002/acn3.51667. Epub 2022 Oct 8. Ann Clin Transl Neurol. 2022. PMID: 36208052 Free PMC article. Clinical Trial.
Design of a Randomized Controlled Clinical Study of tissue-engineered osteogenic materials using bone marrow-derived mesenchymal cells for Maxillomandibular bone defects in Japan: the TEOM study protocol.
Shimizu S, Tsuchiya S, Hirakawa A, Kato K, Ando M, Mizuno M, Osugi M, Okabe K, Katagiri W, Hibi H. Shimizu S, et al. BMC Oral Health. 2019 Apr 30;19(1):69. doi: 10.1186/s12903-019-0753-1. BMC Oral Health. 2019. PMID: 31039763 Free PMC article. Clinical Trial.
Influence of background characteristics in responders of regenerative therapy by periurethral injection of adipose-derived regenerative cells for male stress urinary incontinence.
Yamanishi T, Ishizuka O, Shimizu S, Kobayashi Y, Kinoshita F, Yamamoto T, Mizokami A, Narimoto K, Toriyama K, Kamei Y, Kuwatsuka Y, Mizuno M, Gotoh M. Yamanishi T, et al. Among authors: shimizu s. Low Urin Tract Symptoms. 2022 Jul;14(4):273-280. doi: 10.1111/luts.12433. Epub 2022 Feb 25. Low Urin Tract Symptoms. 2022. PMID: 35218150
Regenerative treatment for male stress urinary incontinence by periurethral injection of adipose-derived regenerative cells: Outcome of the ADRESU study.
Gotoh M, Shimizu S, Yamamoto T, Ishizuka O, Yamanishi T, Mizokami A, Narimoto K, Toriyama K, Kamei Y, Nakayama S, Kuwatsuka Y, Mizuno M, Hirakawa A. Gotoh M, et al. Among authors: shimizu s. Int J Urol. 2020 Oct;27(10):859-865. doi: 10.1111/iju.14311. Epub 2020 Jul 30. Int J Urol. 2020. PMID: 32729155
4,604 results